Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group

William R. Friedenberg; Martin S. Tallman; Isadore Brodsky; Elisabeth Paietta; Jacob M. Rowe; Sandra J. Lee; Kendrith M. Rowland; George W. Schnetzer; John C. Reed

doi:10.1016/j.leukres.2003.12.002

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group

William R. Friedenberg, Martin S. Tallman, Isadore Brodsky, Elisabeth Paietta, Jacob M. Rowe, Sandra J. Lee, Kendrith M. Rowland, George W. Schnetzer, John C. Reed

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

Original language	English (US)
Pages (from-to)	813-819
Number of pages	7
Journal	Leukemia Research
Volume	28
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2003.12.002
State	Published - Aug 2004
Externally published	Yes

Keywords

Chronic lymphocytic leukemia
Multidrug resistance
PSC-833
p-Glycoprotein

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2003.12.002

Cite this

Friedenberg, W. R., Tallman, M. S., Brodsky, I., Paietta, E., Rowe, J. M., Lee, S. J., Rowland, K. M., Schnetzer, G. W., & Reed, J. C. (2004). Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group. Leukemia Research, 28(8), 813-819. https://doi.org/10.1016/j.leukres.2003.12.002

@article{0707ed0885434cbf8a3ea92b25907321,

title = "Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group",

abstract = "Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.",

keywords = "Chronic lymphocytic leukemia, Multidrug resistance, PSC-833, p-Glycoprotein",

author = "Friedenberg, {William R.} and Tallman, {Martin S.} and Isadore Brodsky and Elisabeth Paietta and Rowe, {Jacob M.} and Lee, {Sandra J.} and Rowland, {Kendrith M.} and Schnetzer, {George W.} and Reed, {John C.}",

note = "Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA17145, CA13650 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. ",

year = "2004",

month = aug,

doi = "10.1016/j.leukres.2003.12.002",

language = "English (US)",

volume = "28",

pages = "813--819",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996)

T2 - A trial of the Eastern Cooperative Oncology Group

AU - Friedenberg, William R.

AU - Tallman, Martin S.

AU - Brodsky, Isadore

AU - Paietta, Elisabeth

AU - Rowe, Jacob M.

AU - Lee, Sandra J.

AU - Rowland, Kendrith M.

AU - Schnetzer, George W.

AU - Reed, John C.

N1 - Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA17145, CA13650 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2004/8

Y1 - 2004/8

N2 - Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

AB - Background & method: The role of multidrug resistance (MDR) was investigated in patients with relapsed chronic lymphocytic leukemia (CLL). PSC-833 was added to modified VAD (a 4-day infusion of vincristine, doxorubicin, with oral dexamethasone, every 3 weeks), in an attempt to improve the response rate (21%) in a prior study. Laboratory tests to determine MDR and apoptosis proteins were correlated with response. Results: Two of the seven MDR-positive cases and one of the four MDR-negative patients achieved a partial response (no significant difference). No significant correlation with response was found in any of the laboratory tests for apoptosis. Conclusion: VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

KW - Chronic lymphocytic leukemia

KW - Multidrug resistance

KW - PSC-833

KW - p-Glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=2942622408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942622408&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.12.002

DO - 10.1016/j.leukres.2003.12.002

M3 - Article

C2 - 15203279

AN - SCOPUS:2942622408

SN - 0145-2126

VL - 28

SP - 813

EP - 819

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this